This process is closely related to improve the secretion of intestinal L cell and islet cell, activate GLP-1R/PKA signaling pathway through autocrine and paracrine, and increase the expression of its related molecule such as GLP-1, GLP-1R, PC1/3, PC2, PKA, Pdx1
Reduced Risk of Hypoglycemia : Unlike some other diabetes medications, GLP-1 receptor agonists have a low risk of causing hypoglycemia (dangerously low blood sugar levels)
To this end, Chen et al., has suggested that activation of GLP-1R with liraglutide could protect chondrocytes against endoplasmic reticulum (ER) stress, apoptosis and inflammation by decreasing the release of inflammatory mediators and regulating phosphoinositide 3-kinase (PI3K)/AKT signaling, which suggests that GLP-1R is a therapeutic target for the treatment of OA and that liraglutide could be a therapeutic candidate for clinical application [10]
Both compounds represent powerful tools for optimizing cellular function when used appropriately under expert guidance
According to the National Institutes of Health, 3 out of 4 people suffering from an opioid use disorder have sleep problems
